Phase I study to assess safety, biodistribution and radiation dosimetry for (89)Zr-girentuximab in patients with renal cell carcinoma

PURPOSE: In this phase I study, we evaluated the safety, biodistribution and dosimetry of [(89)Zr]Zr-DFO-girentuximab ((89)Zr-girentuximab) PET/CT imaging in patients with suspicion of clear cell renal cell carcinoma (ccRCC). METHODS: Ten eligible patients received an intravenous administration of 3...

Descripción completa

Detalles Bibliográficos
Autores principales: Merkx, Robin I. J., Lobeek, Daphne, Konijnenberg, Mark, Jiménez-Franco, Luis David, Kluge, Andreas, Oosterwijk, Egbert, Mulders, Peter F.A., Rijpkema, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426244/
https://www.ncbi.nlm.nih.gov/pubmed/33651116
http://dx.doi.org/10.1007/s00259-021-05271-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426244/
https://www.ncbi.nlm.nih.gov/pubmed/33651116
http://dx.doi.org/10.1007/s00259-021-05271-w

Ejemplares similares